Hospital Based Registry of Childhood Cancer in Pediatric Oncology Units in French Speaking Africa
RFAOP
French African Pediatric Oncology Registry
1 other identifier
observational
10,000
10 countries
12
Brief Summary
The ultimate aim of this registry is to collect precise information concerning the children coming to oncology units working with the French African Oncology Group. This data will help to plan and provide correct pediatric oncology treatment and care for this population. Collecting the data will give much needed information on numbers, stage, treatment and outcome. The register will give data for local and national health authorities in planning pediatric cancer programs.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2016
Longer than P75 for all trials
12 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2016
CompletedFirst Submitted
Initial submission to the registry
November 8, 2018
CompletedFirst Posted
Study publicly available on registry
January 15, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2030
October 3, 2025
September 1, 2025
14.9 years
November 8, 2018
September 29, 2025
Conditions
Outcome Measures
Primary Outcomes (4)
Number of children with a suspicion of any type of cancer in a given unit
Number of children with details of : 1. the type of cancer 2. the stage of the identified cancer coming into a given unit
in any 12 month period
VITAL STATUS:
Dead or alive 1. The number of children living 2. the number of children dead
in any 12 month period
Illness status
1. The number of children relapsed, 2. The number of children whos illness has progressed.
in any 12 month period
Treatment Status
1. The number of children who had treatment administered, 2. The number of children who abandoned treatment
in any 12 month period
Eligibility Criteria
All childre with any pediatric cancer types, coming into any one of the participating units in a 12 month period.
You may qualify if:
- Any child presenting at any one of the participating units for treatment
- Any child with any type of cancer
- Any child or adolescent less than 18 years of age.
You may not qualify if:
- No cancer found
- Age greater than 18 years -
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (14)
Hopital Yalgado Ouedraogo
Ouagadougou, 03 BP 7022, Burkina Faso
Centre Hospitalier Universitaire Pédiatrique Charles De Gaulle
Ouagadougou, Burkina Faso
Centre Mère et Enfant CME-FCB (Fondation Chantal Biya)
Yaoundé, Cameroon
CHU de Treichville à ABIDJAN
Abidjan, Abidjan Autonomous District, Côte d’Ivoire
Cliniques Universitaires de Kinshasa
Kinshasa, Kinshasa City, BP 12 KIN XI, Democratic Republic of the Congo
Cliniques Universitaires de Lubumbashi (CUL)
Lubumbashi, BP 1825, Democratic Republic of the Congo
GFAOP
Villejuif, PARIS, 00094, France
l'Institut de Cancérologie de Libreville
Libreville, Gabon
HJRA, Hôpital universitaire Joseph Ravoahangy Andrianavalona
Antananarivo, Ampefiloha, BP 4150, Madagascar
CHU Gabriel Touré (HGT)
Bamako, Mali
Centre National d'Oncologie (CNO)
Nouakchott, Mauritania
CNLC, Centre National de Lutte contre le Cancer
Niamey, Niger
Hôpital Aristide Le Dantec, Avenue Pasteur, BP 3001
Dakar, Dakar, Senegal
CHU Sylvanus Olympio
Lomé, BP 57, Togo
MeSH Terms
Conditions
Study Officials
- STUDY DIRECTOR
Brenda Mallon, MSc
French Africa Pediatric Oncology Group
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 12 Months
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 8, 2018
First Posted
January 15, 2019
Study Start
January 1, 2016
Primary Completion (Estimated)
December 1, 2030
Study Completion (Estimated)
December 1, 2030
Last Updated
October 3, 2025
Record last verified: 2025-09